The Latest Analyst Ratings for Sage Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter, with the majority being indifferent. The average 12-month price target for Sage Therapeutics has decreased by 39.34% from the previous average price target of $48.20 to $29.24.
October 13, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has received various ratings from analysts, with the majority being indifferent. The average 12-month price target has decreased significantly.
The decrease in the average 12-month price target indicates a negative sentiment towards the stock, which could potentially lead to a decrease in its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100